Citations

Showing 10 of 108083 citations.

Sleep Neurology: Is It a Ready for Prime Time Player?
Louis, Erik K. St. , St Louis, Erik K, St Louis, E K

Mayo Clinic

Journal of Clinical Neurophysiology | March 6, 2023 | Volume: 40 | Issue: 3 | Pages: 189-190

10.1097/wnp.0000000000000997 | PMID 36872496 Get It

Pain in individuals with idiopathic inflammatory myopathies, other systemic autoimmune rheumatic diseases, and without rheumatic diseases: A report from the COVAD study
Kim, Minchul , Missé, Rafael Giovani , Naveen, R, Day, Jessica , Cordeiro, Rafael Alves , Júnior, Jucier Gonçalves , Chatterjee, Tulika , Kardeş, Sinan , Milchert, Marcin , Salim, Babur , Velikova, Tsvetelina , Parodis, Ioannis , Selva-O’Callaghan, Albert , Nikiphorou, Elena , Tan, Ai Lyn , Ziadé, Nelly , Kuwana, Masataka , Nune, Arvind , Chinoy, Hector , Agarwal, Vikas , Gupta, Latika, Group, COVAD Study, Singh, Yogesh Preet , Ravichandran, Naveen , Gupta, Latika , Naveen, R , Kardes, Sinan , Gheita, Tamer , Parodis, Ioannis , Selva O'Callaghan, Albert , Saavedra, Miguel A , Ziade, Nelly , Agarwal, Vikas , Gupta, Latika , Milchert, Marcin , Day, Jessica , Velikova, Tsvetelina , Tan, Ai Lyn , Chatterjee, Tulika , Chinoy, Hector , Nune, Arvind , Singh, Yogesh Preet , Shinjo, Samuel Katsuyuki , Hoff, Leonardo Santos , Sen, Parikshit , Lilleker, James B , Agarwal, Vishwesh , Gheita, Tamer A. , Gracia‐Ramos, Abraham Edgar , Makol, Ashima , Cavagna, Lorenzo , Knitza, Johannes , Distler, Oliver , Aggarwal, Rohit , Group, COVAD Study

Mayo Clinic

International Journal of Rheumatic Diseases | March 5, 2023 | Volume: 26 | Issue: 4 | Pages: 727-739

10.1111/1756-185x.14636 | PMID 36872076 Get It

AbstractObjectivesTo compare pain intensity among individuals with idiopathic inflammatory myopathies (IIMs), other systemic autoimmune rheumatic diseases (AIRDs), and without rheumatic disease (wAIDs).MethodsData were collected from the COVID‐19 Vaccination in Autoimmune Diseases (COVAD) study, an international cross‐sectional online survey, from December 2020 to August 2021. Pain experienced in the preceding week was assessed using numeral rating scale (NRS). We performed a negative binomial regression analysis to assess pain in IIMs subtypes and whether demographics, disease activity, general health status, and physical function had an impact on pain scores.ResultsOf 6988 participants included, 15.1% had IIMs, 27.9% had other AIRDs, and 57.0% were wAIDs. The median pain NRS in patients with IIMs, other AIRDs, and wAIDs were 2.0 (interquartile range [IQR] = 1.0–5.0), 3.0 (IQR = 1.0–6.0), and 1.0 (IQR = 0–2.0), respectively (P < 0.001). Regression analysis adjusted for gender, age, and ethnicity revealed that overlap myositis and antisynthetase syndrome had the highest pain (NRS = 4.0, 95% CI = 3.5–4.5, and NRS = 3.6, 95% CI = 3.1–4.1, respectively). An additional association between pain and poor functional status was observed in all groups. Female gender was associated with higher pain scores in almost all scenarios. Increasing age was associated with higher pain NRS scores in some scenarios of disease activity, and Asian and Hispanic ethnicities had reduced pain scores in some functional status scenarios.ConclusionPatients with IIMs reported higher pain levels than wAIDs, but less than patients with other AIRDs. Pain is a disabling manifestation of IIMs and is associated with a poor functional status.
Exposure to Arterial Hyperoxia During Extracorporeal Membrane Oxygenator Support and Mortality in Patients With Cardiogenic Shock
Jentzer, Jacob C. , Miller, P. Elliott , Alviar, Carlos L. , Yalamuri, Suraj , Bohman, J. Kyle , Tonna, Joseph E. , Tonna, Joseph E. , Jentzer, Jacob C , Bohman, John K

Mayo Clinic

Circulation: Heart Failure | March 5, 2023 | Volume: 16 | Issue: 4 | Pages: No page available

10.1161/circheartfailure.122.010328 | PMID 36871240 Get It

Background: Exposure to hyperoxia, a high arterial partial pressure of oxygen (PaO2), may be associated with worse outcomes in patients receiving extracorporeal membrane oxygenator (ECMO) support. We examined hyperoxia in the Extracorporeal Life Support Organization Registry among patients receiving venoarterial ECMO for cardiogenic shock. Methods: We included Extracorporeal Life Support Organization Registry patients from 2010 to 2020 who received venoarterial ECMO for cardiogenic shock, excluding extracorporeal CPR. Patients were grouped based on PaO2 after 24 hours of ECMO: normoxia (PaO2 60–150 mmHg), mild hyperoxia (PaO2 151–300 mmHg), and severe hyperoxia (PaO2 >300 mmHg). In-hospital mortality was evaluated using multivariable logistic regression. Results: Among 9959 patients, 3005 (30.2%) patients had mild hyperoxia and 1972 (19.8%) had severe hyperoxia. In-hospital mortality increased across groups: normoxia, 47.8%; mild hyperoxia, 55.6% (adjusted odds ratio, 1.37 [95% CI, 1.23–1.53]; P <0.001); severe hyperoxia, 65.4% (adjusted odds ratio, 2.20 [95% CI, 1.92–2.52]; P <0.001). A higher PaO2 was incrementally associated with increased in-hospital mortality (adjusted odds ratio, 1.14 per 50 mmHg higher [95% CI, 1.12–1.16]; P <0.001). Patients with a higher PaO2 had increased in-hospital mortality in each subgroup and when stratified by ventilator settings, airway pressures, acid-base status, and other clinical variables. In the random forest model, PaO2 was the second strongest predictor of in-hospital mortality, after older age. Conclusions: Exposure to hyperoxia during venoarterial ECMO support for cardiogenic shock is strongly associated with increased in-hospital mortality, independent from hemodynamic and ventilatory status. Until clinical trial data are available, we suggest targeting a normal PaO2 and avoiding hyperoxia in CS patients receiving venoarterial ECMO.
Rate-Adaptive Atrial Pacing for Heart Failure With Preserved Ejection Fraction
Reddy, Yogesh N.V. , Koepp, Katlyn E. , Carter, Rickey E. , Win, Sithu , Jain, C. Charles , Olson, Thomas P. , Johnson, Bruce D. , Rea, Robert F., Redfield, Margaret M. , Carter, Rickey, Jain, Christopher Charles, Rea, Robert, Nishimura, Rick , Carter, Rickey E , Borlaug, Barry A.

Mayo Clinic

JAMA | March 5, 2023 | Volume: 329 | Issue: 10 | Pages: 801

10.1001/jama.2023.0675 | PMID 36871285 Get It

Importance Reduced heart rate during exercise is common and associated with impaired aerobic capacity in heart failure with preserved ejection fraction (HFpEF), but it remains unknown if restoring exertional heart rate through atrial pacing would be beneficial. Objective To determine if implanting and programming a pacemaker for rate-adaptive atrial pacing would improve exercise performance in patients with HFpEF and chronotropic incompetence. Design, Setting, and Participants Single-center, double-blind, randomized, crossover trial testing the effects of rate-adaptive atrial pacing in patients with symptomatic HFpEF and chronotropic incompetence at a tertiary referral center (Mayo Clinic) in Rochester, Minnesota. Patients were recruited between 2014 and 2022 with 16-week follow-up (last date of follow-up, May 9, 2022). Cardiac output during exercise was measured by the acetylene rebreathe technique. Interventions A total of 32 patients were recruited; of these, 29 underwent pacemaker implantation and were randomized to atrial rate responsive pacing or no pacing first for 4 weeks, followed by a 4-week washout period and then crossover for an additional 4 weeks. Main Outcomes and Measures The primary end point was oxygen consumption (V̇ o 2 ) at anaerobic threshold (V̇ o 2,AT ); secondary end points were peak V̇ o 2 , ventilatory efficiency (V̇ e /V̇ co 2 slope), patient-reported health status by the Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OSS), and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels. Results Of the 29 patients randomized, the mean age was 66 years (SD, 9.7) and 13 (45%) were women. In the absence of pacing, peak V̇ o 2 and V̇ o 2 at anaerobic threshold (V̇ o 2,AT ) were both correlated with peak exercise heart rate ( r = 0.46-0.51, P &amp;lt; .02 for both). Pacing increased heart rate during low-level and peak exercise (16/min [95% CI, 10 to 23], P &amp;lt; .001; 14/min [95% CI, 7 to 21], P &amp;lt; .001), but there was no significant change in V̇ o 2,AT (pacing off, 10.4 [SD, 2.9] mL/kg/min; pacing on, 10.7 [SD, 2.6] mL/kg/min; absolute difference, 0.3 [95% CI, −0.5 to 1.0] mL/kg/min; P = .46), peak V̇ o 2 , minute ventilation (V̇ e) /carbon dioxide production (V̇ co 2 ) slope, KCCQ-OSS, or NT-proBNP level. Despite the increase in heart rate, atrial pacing had no significant effect on cardiac output with exercise, owing to a decrease in stroke volume (−24 mL [95% CI, −43 to −5 mL]; P = .02). Adverse events judged to be related to the pacemaker device were observed in 6 of 29 participants (21%). Conclusions and Relevance In patients with HFpEF and chronotropic incompetence, implantation of a pacemaker to enhance exercise heart rate did not result in an improvement in exercise capacity and was associated with increased adverse events. Trial Registration ClinicalTrials.gov Identifier: NCT02145351
Facial aesthetic minimally invasive procedure: More than just vanity, a social‐psychological approach
Elzen, Helga E. van den, Barends, Ard J. , Vugt, Mark van , Biesman, Brian S. , Alfertshofer, Michael , Cotofana, Sebastian , Cotofana, Sebastian , Alfertshofer, Michael , ELZEN, HELGA J. VAN DEN, Velthuis, Peter J.

Mayo Clinic

Journal of Cosmetic Dermatology | March 5, 2023 | Volume: 22 | Issue: 7 | Pages: 2063-2070

10.1111/jocd.15678 | PMID 36852750 Get It

AbstractBackgroundDue to the great importance of the face in social interaction, minimally invasive treatments can—besides their ability to rejuvenate and enhance beauty—also change the way facial impressions of a person are perceived. In recent literature, three main character traits (attractiveness, trustworthiness, and competence) and subdomains essential for facial perception were described.ObjectiveTo investigate whether minimally invasive procedures truly influence different character traits when evaluated by independent, objective observers.MethodsPhotographs of n = 34 female faces before and after treatment with injectable fillers and botulinum toxin were rated by 393 individuals without aesthetic background with regards to different character traits on a 7‐point Likert scale. Tests for dimensionality were performed, and composite scores of the impressions underlying each of the three dimensions were created and compared using within‐subjects t tests.ResultsTreatments statistically significantly improved the overarching character trait domains attractiveness, trustworthiness, and competence in posttreatment photographs compared with pretreatment. Posttreatment ratings of the respective subdomains also showed a statistically significant difference compared with pretreatment photographs, with the exception of the subdomain dominance which failed to reach statistical significance.ConclusionImpressions of facial attractiveness, trustworthiness, and competence can be improved by injectables while the naturalness of the face is left intact. An implication is that the improvement of traits highly relevant to social interaction will accommodate the patient's desires for beautification and rejuvenation.
Immunomodulators for severe coronavirus disease‐2019 in transplant patients: Do they increase the risk of secondary infection?
Ranganath, Nischal , Chesdachai, Supavit , Yetmar, Zachary A. , Razonable, Raymund R. , Saleh, Omar Abu , Mendoza, Maria A. , Ranganath, Nischal , Chesdachai, Supavit , Yetmar, Zachary A , Razonable, Raymund R , Abu Saleh, Omar

Mayo Clinic

Transplant Infectious Disease | March 5, 2023 | Volume: 25 | Issue: 2 | Pages: No page available

10.1111/tid.14050 | PMID 36852753 Get It

AbstractBackgroundCurrent guidelines recommend immunomodulators, tocilizumab or baricitinib, for the management of severe coronavirus disease‐2019 (COVID‐19) in patients with increasing oxygen requirements. Given their immunosuppressive effects, there is a concern for higher rates of infection among transplant recipients.MethodsA retrospective cohort study of transplant patients with severe COVID‐19 between April 2020 and January 2022 was performed at the Mayo Clinic. The primary outcome was incidence of secondary infections after COVID‐19 diagnosis. Secondary outcomes were 90‐day mortality, ventilatory days, and thromboembolic events.ResultsA total of 191 hospitalized transplant patients were studied, including 77 (40.3%) patients who received an immunomodulator. Overall, 89% were solid organ transplant recipients, with kidney as the most common transplanted organ (50.3%). The majority (89.0%) required oxygen supplementation on admission, and 39.8% of these patients required mechanical ventilation during the hospital course. There was no significant difference in the incidence of secondary infections between those who received or did not receive an immunomodulator (p = .984). Likewise, there was no difference in 90‐day mortality between patients who received or did not receive an immunomodulator (p = .134). However, higher mortality was observed among patients that developed a secondary infection (p < .001).ConclusionThe use of immunomodulators in transplant patients with severe COVID‐19 was not significantly associated with an increased risk of secondary infections. Secondary infections were associated with higher risk of all‐cause mortality. Future studies of larger cohorts are needed to explore the effect of immunomodulators on survival among transplant patients with COVID‐19. image
Clinical Framework for Dismantling Antiblack Racism in the Clinic Room
Herbst, Rachel Becker , McTate, Emily , Herbst, Rachel , McTate, Emily , Corley, Alexandra M. S.

Mayo Clinic

Clinical Pediatrics | March 5, 2023 | Volume: 62 | Issue: 10 | Pages: 1129-1136

10.1177/00099228231156009 | PMID 36852825 Get It

Children who identify as Black or multiracial report significantly higher exposure to adverse childhood experiences, which places them at greater risk for poor mental and physical health outcomes. These disparities and increasing awareness of racism as an adverse childhood experience has resulted in the American Academy of Pediatrics, American Psychological Association, and other groups declaring racism a public health crisis. To provide high-quality care, providers who engage with patients and families impacted by systemic racism must be aware of its role in health disparities. This requires clinicians to have the knowledge and skills to discuss racism with colleagues, patients, and families. To promote clinicians’ competence to engage in these discussions, this article 1) sensitizes providers to historical and contextual factors that inform experiences with anti-Black racism and health disparities and 2) offers strategies to address anti-Black racism in clinical care.Embracing the process of brave, informed conversations about race represents a pathway for building trust between providers and patients, a key component of various health outcomes. Additionally, these foundational skills of reflection, cultural humility, and bias recognition will be needed to engage in allyship and advocacy both within and beyond the exam room.
Vaccine Hesitancy in Mississippi: Does Political Ideology Muddy the Waters?
Evans, Marion W. , Wajpe, Abhishek S. , Wari, Eki, Aras, Sermin , Lemacks, Jennifer

Mayo Clinic

Journal of Primary Care & Community Health | March 5, 2023 | Volume: 14 | Issue: No issue available | Pages: No page available

10.1177/21501319231158518 | PMID 36852739 Get It

During the SARS-CoV2 pandemic vaccines were made available at a rapid pace in the United States (US) with support from the government. In Mississippi, vaccine hesitancy was marked. Across the country many areas of the US demonstrated reduced uptake regarding this specific vaccine due to a variety of reasons. Even with the efficacy of the vaccine indicative of a significant level of protection from mortality and serious morbidity, vaccine uptake and hesitancy were a significant concern. This study surveyed Mississippians on their willingness to take the vaccine or not, and in particular, investigated political ideology as a reason for vaccine hesitancy. Data was collected via an online survey and 589 adults (>18 years) responded. Those self-identifying as “Republican” were more than twice as likely to disagree that not getting the vaccine was a risk to their health and others (OR = 2.07, 95% CI 1.70, 2.54) as those who identified as “Democrat or independent” voters. Future health promotion efforts should specifically attempt to address this group in a more effective manner.
Pediatric Epicardial Devices: Early and Midterm Outcomes
Griffeth, Elaine M. , Krishnan, Prasad , Dearani, Joseph A. , Ackerman, Michael J. , Wackel, Philip L. , Cannon, Bryan C. , Dearani, Joseph A. , Pahwa, Siddharth , Todd, Austin W.

Mayo Clinic

World Journal for Pediatric and Congenital Heart Surgery | March 5, 2023 | Volume: 14 | Issue: 4 | Pages: 451-458

10.1177/21501351231157374 | PMID 36851830 Get It

Background Lead performance is suboptimal in young patients and a main cause of device system failure. Our objective was to assess early and midterm outcomes after epicardial device implantation in a contemporary pediatric cohort. Methods A total of 116 consecutive pediatric patients underwent 137 epicardial device implantations from 2010 to 2019. Forty pacemakers and 97 implantable cardioverter defibrillators (ICDs) were implanted. Lead failure was defined as leads repaired, replaced, or abandoned due to fracture, dislodgement, or dysfunction. Freedom from device system failure was determined using Kaplan-Meier analysis. Results Mean age at implantation was 10 ± 5 years, 46 (34%) were younger than 8 years old, 41 (30%) had prior cardiac surgery, and 38 (28%) had prior devices. Main indications were acquired heart block (17/40 [43%]), sinus node dysfunction (14/40 [35%]), and congenital heart block (7/40 [18%]) for pacemakers, and hypertrophic cardiomyopathy (46/97 [47%]), long QT syndrome (31/97 [32%]), and ventricular arrhythmia (17/97 [18%]) for ICDs. There were no early deaths. Three-year freedom from device system failure was 80% (95% CI 73%, 88%) for all patients and 88% (95% CI 79%, 99%) for patients <8 years old. Device system failure causes included lead fracture (20/34 [59%]), lead dysfunction (5/34 [15%]), lead dislodgement (5/34 [15%]), infection (3/34 [9%]), and pericarditis (1/34 [3%]). Reintervention was required in 26/34 (76%) device system failures. Conclusions Epicardial device implantation is safe, shows acceptable midterm outcomes in children, and is an effective option in patients younger than 8 years old. Close device surveillance continues to be essential to detect lead failure early and ensure timely reintervention.
Characteristics and outcomes of patients with gastroparesis using enteral and/or exclusive parenteral nutrition
Parkman, Henry P. , Murray, Helen Burton , Yates, Katherine P. , Grover, Madhusudan , Malik, Zubair , Schey, Ron , Bulat, Robert, Koch, Kenneth L. , Sarosiek, Irene , Shulman, Robert J. , Farrugia, Gianrico , Miriel, Laura , Tonascia, James , Hamilton, Frank A., Pasricha, Pankaj J. , McCallum, Richard W. , Abell, T L , Parkman, H P , Burton-Murray, Helen , Blackford, Amanda , Kuo, Braden , Chumpitazi, Bruno P. , Abell, Thomas L.

Mayo Clinic

Journal of Parenteral and Enteral Nutrition | March 4, 2023 | Volume: 47 | Issue: 4 | Pages: 541-549

10.1002/jpen.2493 | PMID 36871132 Get It

AbstractBackgroundPatients with gastroparesis (Gp) may need enteral nutrition (EN) or exclusive parenteral nutrition (PN). Among patients with Gp, we aimed to (1) identify the frequency of EN and exclusive PN use and (2) explore characteristics of patients using EN and/or exclusive PN compared with those using oral nutrition (ON), including changes over 48 weeks.MethodsPatients with Gp underwent history and physical examination, gastric emptying scintigraphy, water load satiety testing (WLST), and questionnaires assessing gastrointestinal symptoms and quality of life (QOL). Patients were observed 48 weeks.ResultsOf 971 patients with Gp (idiopathic, 579; diabetic, 336; post–Nissen fundoplication, 51), 939 (96.7%) were using ON only, 14 (1.4%) using exclusive PN, and 18 (1.9%) using EN. Compared with patients receiving ON, patients receiving exclusive PN and/or EN were younger, had lower body mass index, and had greater symptom severity. Patients receiving exclusive PN and/or EN had lower physical QOL but not mental QOL or Gp‐related QOL scores. Patients receiving exclusive PN and/or EN ingested less water during WLST but did not have worse gastric emptying. Of those who had been receiving exclusive PN and/or EN, 50% and 25%, respectively, resumed ON at 48‐week follow‐up.ConclusionsThis study describes patients with Gp requiring exclusive PN and/or EN for nutrition support, who represent a small (3.3%) but important subset of patients with Gp. Unique clinical and physiological parameters are associated with this subset and provide insight into the use of nutrition support in Gp.